Nivalin (Galantamine Hydrobromide)

Galantamine Hydrobromide, the active ingredient in Nivalin, is an acetylcholinesterase inhibitor presented as an unspecified injectable solution for intramuscular, intravenous, subcutaneous use. It is used to treat Alzheimer’s disease in adult patients. GNH USA supplies Nivalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Galantamine Hydrobromide is an acetylcholinesterase inhibitor indicated for cognitive disorders within the Alzheimer’s disease spectrum.

Alzheimer's disease (mild to moderate): improves cognition, memory and daily functioning in patients with diagnosed Alzheimer’s disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis. - Diarrhea: loose stools. - Loss of appetite: reduced food intake. - Dizziness: transient light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate. - Syncope: fainting episodes. - Severe vomiting: risk of dehydration. - Hepatotoxicity: abnormal liver enzymes. - Seizures: rare convulsive events. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and safety measures.

Renal impairment: dose may need adjustment in severe renal dysfunction. Hepatic disease: monitor liver function tests regularly. Cardiac conditions: caution in patients with conduction abnormalities or bradyarrhythmias. Concomitant cholinergic drugs: avoid additive cholinergic effects. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Galantamine may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Anticholinergic agents: may diminish therapeutic effect. - Beta‑blockers: can exacerbate bradycardia. - CYP2D6 inhibitors (e.g., fluoxetine): increase galantamine plasma levels.

Moderate Interactions (Monitor Closely): - Other acetylcholinesterase inhibitors: additive cholinergic toxicity. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - NSAIDs: monitor for gastrointestinal irritation.